The Sarmguide database lists every compound we cover: SARMs such as ostarine, LGD-4033 and RAD-140, the compounds often sold next to them (MK-677 and cardarine), the drugs studied for post-cycle therapy, and research peptides. Each row shows what published human studies found, and every value links to its source on the compound’s own page.
Search by name or alias (MK-2866, ligandrol, ibutamoren), filter by type or by what a compound was researched for, and select a column heading to sort.
24 compounds
| AC-262AC-262536, AC-262,536 | SARM | — | Preclinical | 0 | Prohibited at all times | Moderate animal data | Very limited |
|---|---|---|---|---|---|---|---|
| ACP-105ACP105 | SARM | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| AnastrozoleArimidex | PCT & hormonal | ~2–2.1 days | Approved | 396† (PubMed trial records) | Prohibited at all times | None found human data | Moderate |
| Andarine (S4)S-4, S4 | SARM | — | Preclinical | 0 | Prohibited at all times | Moderate animal data | Very limited |
| BPC-157BPC 157, Body Protection Compound-157 | Peptide | — | Phase 2 | 5 | Prohibited at all times | Not measured | Very limited |
| CardarineGW501516, GW-501516 | Other | — | Phase 2 | 4 | Prohibited at all times | Not measured | Moderate |
| CJC-1295CJC 1295, CJC-1295 with DAC | Peptide | ~5.8–8.1 days | Phase 2 | 3 | Prohibited at all times | Not measured | Limited |
| ClomipheneClomifene, Clomiphene citrate | PCT & hormonal | ~5–24 h | Approved | 815† (PubMed trial records) | Prohibited at all times | None found human data | Moderate |
| EnclomipheneEnclomifene, Enclomiphene citrate | PCT & hormonal | ~8–10 h | Phase 3 | 7† (PubMed trial records) | Prohibited at all times | None found human data | Moderate |
| GHK-CuCopper peptide, Copper tripeptide-1 | Peptide | — | — | 3 | Not named – uncertain (may fall under S0) | Not measured | Limited |
| IGF-1 LR3Long R3 IGF-1, LR3IGF-I | Peptide | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| IpamorelinIpamorelin acetate | GH secretagogue | ~2 h | Phase 2 | 2 | Prohibited at all times | Not measured | Limited |
| LGD-4033Ligandrol, VK5211 | SARM | ~24–36 h | Phase 2 | 2 | Prohibited at all times | Marked human data | Moderate |
| MK-677Ibutamoren, Ibutamoren mesylate | GH secretagogue | — | Phase 3 | 17 | Prohibited at all times | Mild human data | Strong |
| MOTS-cMOTS-C, Mitochondrial open reading frame of the 12S rRNA-c | Peptide | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| OstarineEnobosarm, MK-2866 | SARM | ~14–24 h | Phase 3 | 8 | Prohibited at all times | Moderate human data | Strong |
| RAD-140Testolone, Vosilasarm | SARM | ~45 h | Phase 1/2 | 1 | Prohibited at all times | Moderate animal data | Limited |
| RAD-150TLB-150, RAD150 | SARM | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| S-23S23, SARM S-23 | SARM | — | Preclinical | 0 | Prohibited at all times | Moderate animal data | Very limited |
| SR9009Stenabolic, SR-9009 | Other | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| TamoxifenTamoxifen citrate, Nolvadex | PCT & hormonal | ~5–7 days | Approved | 2,342† (PubMed trial records) | Prohibited at all times | None found human data | Moderate |
| TB-500TB500, Thymosin beta-4 fragment (17-23) | Peptide | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
| TesamorelinEgrifta, Egrifta SV | Peptide | ~8–11 min | Approved | 15† (PubMed trial records) | Prohibited at all times | None found human data | Strong |
| YK-11YK11, Myostine | SARM | — | Preclinical | 0 | Prohibited at all times | Not measured | Very limited |
Suppression: "human data" means testosterone was measured in people; "animal data" means the score rests on animal studies because it was not measured in men; "None found" means it was measured and did not fall; "Not measured" means there are no data, which is not the same as no suppression.
How studies are counted: "Human studies" is the number of published human treatment studies we found and read for a compound (trials and other studies that gave it to people). Animal, cell and anti-doping excretion studies are not counted, and a single case report is not a study. Searches of PubMed and ClinicalTrials.gov were last run on 30 Oct 2026.
† For drugs with hundreds of trials (Anastrozole, Clomiphene, Enclomiphene, Tamoxifen, and Tesamorelin), the number is the PubMed records typed Clinical Trial or RCT that mention the drug, not studies read one by one. The count is a floor, not a census, and not a measure of quality.
Every value links to its source on the compound page. Data last checked 30 Oct 2026.
What each column means
| Column | What it shows |
|---|---|
| Half-life | How long it takes for blood levels to fall by half in people, as a range where studies differ. A dash means we found no human study that measured it. For MK-677, for example, the only half-life figures we found online came from sellers and blogs, so we leave it blank. |
| Research stage | The furthest phase of human trials the compound reached (“Phase 1/2” when its furthest trial is a combined phase 1/2 trial). “Approved” means it is an approved medicine somewhere, usually for a different use: tamoxifen and anastrozole for breast cancer, clomiphene for ovulation problems in women, tesamorelin for abdominal fat in HIV. |
| Human studies | The number of published human treatment studies we found and read. Animal, cell and anti-doping excretion studies are not counted, and a single case report is not a study. For drugs with hundreds of trials (marked †), it is the number of PubMed records typed Clinical Trial or RCT. It is a floor, not a census: for ostarine we count 8 trials with results, while the developer states its safety database covers 27 trials (a company figure). The searches were last run on 30 October 2026. |
| WADA | Status on the 2026 World Anti-Doping Agency Prohibited List. See SARMs and WADA for the list sections. |
| Suppression | A Sarmguide score from 0 to 3 (none found, mild, moderate, marked) for how much natural testosterone fell in the cited studies, marked “human data” when it was measured in people and “animal data” when it rests on animal studies. “Not measured” means there are no data, which is not the same as “none found”. |
| Evidence | A Sarmguide score from 0 to 3 (very limited, limited, moderate, strong) for how much human research exists and how good it is. Animal-only compounds score lowest; compounds with large controlled trials score highest. |
How the data is collected
Every value comes from a source we opened and read: PubMed records and full papers, ClinicalTrials.gov results, drug labels on DailyMed, regulator documents (FDA, EMA, TGA, Health Canada) and the WADA Prohibited List. Each finding carries an evidence label (trial, case report, animal, lab analysis, regulator review) so you can see what kind of study it rests on. When no reliable source exists, the database says “not established” instead of guessing. Forum reports and seller claims are not used as evidence. The full process is on our methodology page.
What the database cannot tell you
- Research doses are not product doses. Trials used small, measured doses (ostarine at 0.1 to 3 mg a day in a trial in older adults, for example). Products sold online often do not match their label: in a 2017 analysis of 44 products sold as SARMs, only 52% contained a SARM and only 41% held the amount on the label (Van Wagoner 2017).
- Trials were short and small. Most lasted weeks to a few months, in older adults or patients. A 2026 review notes that serious harms such as cholestatic liver injury appear mostly in case reports of higher-dose, stacked and unmonitored use (Adolf 2026).
- No SARM is an approved medicine. None has been approved in more than 25 years of development (Adolf 2026), and the FDA says products sold as SARMs are unapproved drugs, not dietary supplements (FDA).
Fact sheets
Every compound in the table has a fact sheet with its studies, side effects, charts and sources:
- SARMs: ostarine, LGD-4033, RAD-140, YK-11, S-23, andarine (S4), RAD-150, AC-262,536 and ACP-105
- Often sold with SARMs: MK-677, cardarine and SR9009
- PCT and hormonal: enclomiphene, clomiphene, tamoxifen and anastrozole
- Peptides: BPC-157, TB-500, ipamorelin, CJC-1295, tesamorelin, IGF-1 LR3, MOTS-c and GHK-Cu
How far each compound got in research
Source: Sarmguide compound database.
More charts from the database, free to embed with a credit link, are on the charts page.
Tools built on this data
- Compare: two compounds side by side.
- Stack checker: where the reported risks of several compounds overlap.
- PCT planner: when each compound is cleared and what studies say about suppression.
- Goal finder: a reading path through the research for one goal.
- Legal status by country, WADA status and the glossary.
New to the topic? Start here for what SARMs are, what the evidence shows and the main risks.